AR046077A1 - Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos - Google Patents

Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos

Info

Publication number
AR046077A1
AR046077A1 ARP040102558A ARP040102558A AR046077A1 AR 046077 A1 AR046077 A1 AR 046077A1 AR P040102558 A ARP040102558 A AR P040102558A AR P040102558 A ARP040102558 A AR P040102558A AR 046077 A1 AR046077 A1 AR 046077A1
Authority
AR
Argentina
Prior art keywords
derivatives
cycloalkyl
citimidine
oxicarbonilcitimidine
eleaboration
Prior art date
Application number
ARP040102558A
Other languages
English (en)
Inventor
Li Jinliang
He Baofang
Shao Lanying
Wang Lei
Original Assignee
Shangai Desano Chemical Pharma
Shangai Desano Pharmaceutcal H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shangai Desano Chemical Pharma, Shangai Desano Pharmaceutcal H filed Critical Shangai Desano Chemical Pharma
Publication of AR046077A1 publication Critical patent/AR046077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se revelan derivados de N4-oxicarbonil-citimidina de fórmula general (1) y su preparación. También se revelan esquemas de reacción para preparar el medicamento anticáncer carbamato de fluorocitosina, capecitabina. Estos esquemas de reacción presentan las ventajas de su bajo costo y la gran calidad y alto rendimiento del producto obtenido. Reivindicación 1: Derivados de citimidina, caracterizados porque poseen la estructura de fórmula general (1), donde R1 representa grupos alquilo, cicloalquilo, alquenilo, aralquilo o arilo; R2 representa grupos halógeno, de preferencia flúor o yodo, o un grupo vinilo, etinilo o vinil/etinilo sustituido por halógeno, alquilo, cicloalquilo, cicloalquilo aromático o un radical aromático heterocíclico.
ARP040102558A 2004-02-23 2004-07-20 Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos AR046077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100164722A CN100383128C (zh) 2004-02-23 2004-02-23 N4－氧羰基胞嘧啶衍生物及制备方法与应用

Publications (1)

Publication Number Publication Date
AR046077A1 true AR046077A1 (es) 2005-11-23

Family

ID=34868233

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102558A AR046077A1 (es) 2004-02-23 2004-07-20 Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos

Country Status (3)

Country Link
CN (1) CN100383128C (es)
AR (1) AR046077A1 (es)
WO (1) WO2005080351A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524960A (ja) 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
AR064165A1 (es) * 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
RU2536492C2 (ru) 2008-08-01 2014-12-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Применение 5-фторцитозина в качестве фунгицида
WO2010061402A2 (en) * 2008-11-25 2010-06-03 Vishwanath Kannan An improved process for the preparation of capecitabine
EP2210895A1 (en) * 2009-01-27 2010-07-28 F. Hoffmann-La Roche AG Process for the recovery of beta-Acetylfuranoside
CN101987857A (zh) * 2009-08-07 2011-03-23 合肥华方医药科技有限公司 一种抗肿瘤药物卡培他滨及其中间体的合成方法
CN101830953A (zh) * 2010-05-26 2010-09-15 南京亚东启天药业有限公司 一种卡培他滨及其中间体的制备方法
CN101928314A (zh) * 2010-08-27 2010-12-29 广东肇庆星湖生物科技股份有限公司 一种卡培他滨的制备方法
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
CN102924548B (zh) * 2012-11-30 2015-05-20 安润医药科技（苏州）有限公司 卡培他滨的合成方法
CN103897005B (zh) * 2012-12-27 2017-07-28 鲁南制药集团股份有限公司 一种连续操作合成卡培他滨的方法
CN103333119A (zh) * 2013-05-28 2013-10-02 中国药科大学 1,2-二氢-6-甲基-4-取代氨基-5-嘧啶羧酸类化合物及其制备方法和用途
CN103772453A (zh) * 2014-03-04 2014-05-07 大连大学 β-榄香烯取代乙基全乙酰化糖配合物、β-榄香烯取代乙基糖配合物、制备方法及用途
CN104478975A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种卡培他滨的合成方法
CN104926901B (zh) * 2015-06-15 2018-04-20 广安凯特制药有限公司 一种卡培他滨关键中间体的合成方法
CN105566419A (zh) * 2015-12-28 2016-05-11 上海金和生物技术有限公司 卡培他滨的制备方法
CN111072734B (zh) * 2019-12-11 2023-04-07 中国科学院昆明植物研究所 一种尿嘧啶核苷衍生物及该衍生物制备去氧氟尿苷药物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives

Also Published As

Publication number Publication date
CN1660819A (zh) 2005-08-31
CN100383128C (zh) 2008-04-23
WO2005080351A1 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
AR046077A1 (es) Derivados de n4- oxicarbonilcitimidina, procedimientos de eleaboracion y usos de los mismos
RU2324684C2 (ru) Пиримидиновые производные
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
CY1118723T1 (el) Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης
CY1117132T1 (el) Παραγωγο θειαζολιου
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CY1110738T1 (el) Παραγωγα aminoαλκυλβενζοϋλ-βενζοφουραν ή βενζοθειοφαιν, μεθοδος παρασκευης τους και συνθεσεις που τα περιεχουν
DE502004012095D1 (de) Verfahren zum herstellen von 2-dihalogenacyl-3-amino-acryls ureestern und 3-dihalogenmethyl-pyrazol-4-carbons ureestern
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
DE602005016261D1 (de) Substituierte arylaminderivate und verwendungsverfahren
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
NO20055977L (no) Nye benzimidazolderivater
CY1107875T1 (el) Παραγωγα αμινοκινολινης και η χρηση τους ως συνδετες των α3 αδενοσινης
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
RU2004113111A (ru) Производные индола в качестве ингибиторов сох 11
BRPI0409049A (pt) métodos de preparação de um composto, composição e composição cristalina
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας
ECSP099651A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
AR055113A1 (es) Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicos
KR20220123223A (ko) 이타코네이트 및 메틸 이타코네이트의 프로드러그

Legal Events

Date Code Title Description
FB Suspension of granting procedure